16:07 EST Harmony Biosciences (HRMY) files automatic mixed securities shelf
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Financial Performance and Strategic Settlements Drive Buy Rating
- Harmony Biosciences reports Q4 EPS $1.08, consensus 82c
- Harmony Biosciences price target lowered to $42 from $52 at Mizuho
- Concerns Over Harmony Biosciences: FDA Setback, Patent Risks, and High-Risk Pipeline
- Harmony Biosciences: Buy Rating Affirmed Despite FDA Setback, Strong Growth Potential in Pitolisant Franchise and Pipeline Opportunities